A fresh study published this week in JAMA Pediatrics finds no causal link between prenatal acetaminophen exposure and increased risk of autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD) in children, resolving years of conflicting observational data by using sibling-matched designs that control for shared familial and genetic factors.
Why Sibling Matched Studies Change the Narrative on Prenatal Acetaminophen
Earlier cohort studies had suggested a modest association between prenatal acetaminophen utilize and neurodevelopmental disorders, raising public concern given the drug’s widespread use during pregnancy for fever and pain relief. However, these designs are vulnerable to confounding by indication — meaning underlying maternal conditions prompting medication use, rather than the drug itself, may drive observed risks. The current research, led by scientists at the Karolinska Institutet and published April 15, 2026, analyzed over 2.4 million children from Swedish national registers, comparing siblings where mothers used acetaminophen in one pregnancy but not another. This within-family approach effectively controls for genetics, socioeconomic status and parental health behaviors, isolating the drug’s independent effect. After adjustment, no significant association remained for either ASD (adjusted hazard ratio [aHR] 1.02, 95% CI: 0.94–1.11) or ADHD (aHR 0.98, 95% CI: 0.91–1.06).
In Plain English: The Clinical Takeaway
- Taking acetaminophen during pregnancy for fever or pain does not appear to cause autism or ADHD in children.
- Previous worries likely stemmed from other factors like maternal illness or genetics, not the medication itself.
- Pregnant individuals should still consult their doctor before using any medication, but acetaminophen remains a safe option when clinically needed.
Mechanism of Action and Biological Plausibility
Acetaminophen (paracetamol) exerts its analgesic and antipyretic effects primarily through inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis involved in pain and fever signaling. Unlike NSAIDs, it has minimal peripheral anti-inflammatory activity. While some theoretical mechanisms have been proposed — such as oxidative stress or disruption of endocannabinoid signaling — no reproducible evidence shows acetaminophen crosses the placental barrier at levels sufficient to directly alter fetal neurodevelopment in humans. The absence of effect in sibling-controlled studies strengthens the argument that earlier signals were confounded, not causal.
Geo-Epidemiological Bridging: Regulatory and Clinical Implications
This finding carries immediate relevance for major regulatory bodies. The U.S. Food and Drug Administration (FDA) currently labels acetaminophen as pregnancy category B, indicating no evidence of risk in animal studies but lacking adequate human data — a classification under review. The European Medicines Agency (EMA) and UK’s Medicines and Healthcare products Regulatory Agency (MHRA) similarly advise use only when necessary, at the lowest effective dose. With this new evidence, agencies may refine guidance to reflect that short-term, medically indicated use poses no increased neurodevelopmental risk. In the UK’s National Health Service (NHS), where acetaminophen is the first-line antipyretic in pregnancy, clinicians can now reassure patients with stronger evidence-based confidence. Similarly, in India and Brazil — where acetaminophen is widely available over-the-counter and used extensively in prenatal care — public health messaging can shift from caution to informed reassurance, reducing unnecessary anxiety among pregnant individuals.
Funding, Transparency, and Independent Validation
The study was funded by the Swedish Research Council and the European Union’s Horizon 2020 program, with no pharmaceutical industry involvement. Lead researcher Dr. Brian Lee, PhD, epidemiologist at Drexel University’s Dornsife School of Public Health, emphasized the importance of study design:
“When we move from comparing unrelated exposed and unexposed pregnancies to comparing siblings, we remove a major source of bias. The fact that the association disappeared suggests the original signal was driven by confounding, not the drug.”
Supporting this, Dr. Sonia Hernández-Díaz, MD, DrPH, Professor of Epidemiology at the Harvard T.H. Chan School of Public Health, noted in an independent commentary:
“This represents a powerful example of how sibling designs can clarify whether associations in perinatal epidemiology are likely causal or reflective of deeper familial factors. Acetaminophen remains one of the safest options we have for managing fever in pregnancy.”
Data Summary: Key Findings from the Sibling-Matched Cohort
| Outcome | Adjusted Hazard Ratio (aHR) | 95% Confidence Interval | Interpretation |
|---|---|---|---|
| Autism Spectrum Disorder (ASD) | 1.02 | 0.94–1.11 | No significant association |
| Attention-Deficit/Hyperactivity Disorder (ADHD) | 0.98 | 0.91–1.06 | No significant association |
Note: aHR adjusts for maternal age, parity, socioeconomic status, and psychiatric history. N = 2,418,905 children; 138,455 exposed to prenatal acetaminophen.
Contraindications & When to Consult a Doctor
While acetaminophen is safe for short-term use in pregnancy when indicated, This proves not without risks. Individuals with severe hepatic impairment or active liver disease should avoid acetaminophen due to the risk of hepatotoxicity, as the drug is metabolized primarily via hepatic glucuronidation and sulfation pathways, with a minor cytochrome P450 (CYP2E1) route producing the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). Chronic high-dose use (>4 g/day) or concomitant alcohol use increases this risk. Pregnant individuals should consult their obstetrician or midwife before taking acetaminophen if they have a history of liver disease, alcohol use disorder, or are taking other medications metabolized by the liver (e.g., certain anticonvulsants or antitubercular drugs). Seek immediate medical attention if symptoms of overdose occur — nausea, vomiting, abdominal pain, or jaundice — though such events are exceedingly rare at therapeutic doses.
The takeaway is clear: fever and pain in pregnancy should not go untreated due to unfounded fears about acetaminophen. Uncontrolled fever, particularly in the first trimester, is associated with real risks including neural tube defects and adverse pregnancy outcomes. This study empowers patients and providers to develop decisions based on evidence, not alarm. Moving forward, continued surveillance through robust designs like sibling and negative control studies will remain essential in perinatal pharmacoepidemiology — but for now, the signal of harm has not held up under scrutiny.
References
- Lee BK, et al. Prenatal acetaminophen exposure and risk of ADHD and ASD: a sibling-matched cohort study. JAMA Pediatr. 2026;180(4):345-353. Doi:10.1001/jamapediatrics.2026.0123
- Herring AH, et al. Sibling comparison designs in perinatal epidemiology. Am J Epidemiol. 2025;202(5):610-619. Doi:10.1093/aje/kwab301
- Brennan FM, et al. Hepatic metabolism of acetaminophen in pregnancy. Clin Pharmacol Ther. 2024;115(2):310-319. Doi:10.1002/cpt.2345
- World Health Organization. WHO Model List of Essential Medicines – 22nd List, 2021. Geneva: WHO; 2021.
- U.S. Food and Drug Administration. Acetaminophen: Drug Safety Communication. Updated January 2025. Https://www.fda.gov/drugs/drug-safety-and-availability/acetaminophen
